EnGeneIC is an Australian biopharmaceutical company developing EDV™ (EnGeneIC Dream Vector) nanocells, a first-in-class cyto-immunotherapy platform for targeted cancer treatment. The proprietary technology delivers chemotherapeutics and functional nucleic acids directly to tumors while leveraging the patient's immune system for enhanced efficacy. The company is advancing its EGFR-targeted EDV platform through Phase I/IIa clinical trials in partnership with Mater Hospital Sydney and international sites, with manufacturing scaled through CDMO partner BioCina. Signal Plug searches live against engeneic.com's mail server to find and verify email addresses for any EnGeneIC employee.
Signal Plug searches live against engeneic.com's mail server — not a static database. Get a verified email for any EnGeneIC employee with confidence score in under 2 seconds.
94% accuracy · No credit card required · 10 free searches/month
EnGeneIC is an Australian biopharmaceutical company developing EDV™ (EnGeneIC Dream Vector) nanocells, a first-in-class cyto-immunotherapy platform for targeted cancer treatment. The proprietary technology delivers chemotherapeutics and functional nucleic acids directly to tumors while leveraging the patient's immune system for enhanced efficacy. The company is advancing its EGFR-targeted EDV platform through Phase I/IIa clinical trials in partnership with Mater Hospital Sydney and international sites, with manufacturing scaled through CDMO partner BioCina.
Competitive Advantage
EnGeneIC's EDV platform is specifically designed to leverage patient's own immune system alongside cytotoxic chemotherapy for dual-mechanism cancer targeting. The company selected a global CDMO partner for manufacturing, indicating confidence in scalability and commercial viability of the nanocell technology. Australian-based biopharmaceutical company pursuing international clinical trial expansion, suggesting global commercial aspirations. EDV platform can be loaded with different payloads (chemotherapeutics or immune-stimulating adjuvants), providing modular therapeutic flexibility. Early-stage clinical trial at prestigious Mater Hospital Sydney demonstrates validation by established oncology research institutions.
The most commonly verified format at EnGeneIC:
Medium ConfidenceSignal Plug tests all common patterns against EnGeneIC's live mail server and returns whichever passes the SMTP check.
Run a live search for EnGeneIC →Data-driven signals to help you prospect EnGeneIC effectively.
EnGeneIC targets pharmaceutical investors, strategic partners in oncology, and contract manufacturing organizations seeking innovative cancer therapy platforms. The company attracts talent in biotech, immunotherapy, nanotechnology, and clinical development seeking cutting-edge therapeutic innovation.
Primary Contact
Oncology physicians
Tuesday–Thursday, 9am–11am
Signal Plug performs live SMTP verification against engeneic.com's mail server — not a static scraped database — which means results reflect the real, current state of EnGeneIC's email infrastructure. Here's how to run a lookup:
Create a free account
Sign up at Signal Plug in under 30 seconds. No credit card required. The Free plan includes 10 searches per month so you can test the tool with real EnGeneIC contacts before upgrading.
Enter the contact's name
Type the first and last name of the EnGeneIC employee you want to reach. Signal Plug handles all seniority levels, from C-suite to individual contributors.
Enter the domain
Use engeneic.com. Signal Plug tests all common naming patterns automatically and returns only the format that passes the SMTP check.
Get a verified result
Signal Plug returns an email address with a confidence score (0–100) and deliverability status (Valid, Risky, or Catch-all) within 2 seconds. The confidence score tells you how reliable the result is before you use it.
Export and use
One-click CSV export lets you bring EnGeneIC contacts into Salesforce, HubSpot, Outreach, Lemlist, or any other tool in your stack. Growth and Scale plan users can run bulk lookups across an entire list of EnGeneIC names in a single batch.
Whether you're running outbound sales, recruiting, or building a partnership list, these are the roles most frequently contacted at Biopharmaceutical like EnGeneIC.
Based on EnGeneIC's profile, the highest-value contacts for outbound are:
Signal Plug works for any role at any seniority level at engeneic.com. If you have a name and the domain, you can find a verified email.
How well EnGeneIC fits a typical B2B outbound pipeline, based on available signals.
Good Fit
Funnel Fit Score
Most email finder tools pull from static databases of scraped email addresses. These databases go stale as people change jobs and companies update their email infrastructure. Signal Plug takes a different approach: every search performs a live check against engeneic.com's mail server using SMTP verification. This means results reflect the current state of EnGeneIC's email system — not a cached result from months or years ago.
Signal Plug enriches every result with supporting data: a confidence score (0–100), deliverability status (Valid, Risky, or Catch-all), job title where available, and LinkedIn profile URL. This context helps you prioritize which EnGeneIC contacts to email first and personalize your outreach before you hit send. Plans start at $29/month for 500 searches — no annual contracts or seat fees.
Signal Plug performs a live SMTP check against engeneic.com's mail server for every query — not a static database lookup. Our platform-wide accuracy rate is 94%. Each result comes with a confidence score (0–100) so you can gauge reliability before using the address.
Free plan: 10 searches. Starter ($29/mo): 500. Growth ($149/mo): 2,000. Scale ($299/mo): 5,000. No company-specific caps.
No. Signal Plug generates and verifies emails in real time via SMTP checks — no static database of EnGeneIC employee emails is maintained.
Yes. Growth and Scale plan users can upload a CSV of names and run bulk lookups against engeneic.com in a single batch.
EDV™ (EnGeneIC Dream Vector) is a first-in-class cyto-immunotherapy platform that delivers chemotherapeutics directly to tumors while stimulating the patient's immune system for enhanced anti-cancer activity.
The company is advancing Phase I/IIa clinical trials with its EGFR-targeted EDV platform carrying the drug PNU-159682, with trials ongoing in Sydney and planned international expansion.
Current development focuses on advanced solid tumors expressing Epidermal Growth Factor Receptor (EGFR), with potential for broader applications.
BioCina, a global CDMO, partners with EnGeneIC for technology transfer, process scale-up, and GMP batch manufacture of EDV nanocells.
Signal Plug searches in real time against engeneic.com's mail server to find and verify email addresses for EnGeneIC employees. Enter a name, enter the domain, get a verified result with a confidence score in under 2 seconds.
Start finding emails free →10 free searches · No credit card required · Upgrade from $29/month